Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

INTRODUCTION: Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Dermatol Ther (Heidelb)
Autors principals: Armstrong, April, Paul, Carle, Puig, Luis, Boehncke, Wolf Henning, Freeman, Michael, Torii, Hideshi, Papp, Kim, Griffiths, Christopher E. M., Blauvelt, Andrew, Reich, Kristian, Gooderham, Melinda, Terui, Tadashi, Renda, Lisa, Agada, Noah, Xu, Wen, Gallo, Gaia, Lebwohl, Mark G.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994584/
https://ncbi.nlm.nih.gov/pubmed/31749092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-019-00340-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars